Interventional Radiologists at the University of Michigan Health Save Patient’s Leg in a First-in-Human Compassionate Use of VeinWay’s Traversa

Ann Arbor, Michigan and Or Yehuda, Israel, March 2, 2023 — In a first-in-human, compassionate use case approved by the U.S. Food and Drug Administration, University of Michigan Health Interventional Radiologists Dr. David M. Williams and Dr. Minhaj S. Khaja successfully used VeinWay’s Traversa for venous recanalization to save a patient’s leg that was close to being amputated.

                                                      Mr. Jordan Pollack, CEO, VeinWay (left) and Dr. Minhaj S. Khaja (right) on the day of the procedure. 


Traversa, a newly developed tool for crossing tough occlusions in veins, enabled the physicians to recanalize a previously uncrossable vascular pathway, which included a 20 cm long blocked vein with four occluded stents.

University of Michigan Health Interventional Radiologist Dr. David M. Williams, “I had crossed the segment in this patient three years ago, but today it would have been impossible with existing devices. The patient’s leg was in desperate condition. Traversa not only made this procedure possible, but also much easier and impressively faster.”

University of Michigan Health Interventional Radiologist Dr. Minhaj S. Khaja said, “The device allowed us to take the path that we wanted rather than being forced to trouble shoot the path chosen by the sharp recanalization devices available today. With Traversa, we were able to choose the angle and the length of the throw of the needle. This enabled us to pick the pathway and if we didn’t like it, we were able to readjust. I think that allowed us to safely get through the occlusions and the stents.”

VeinWay CEO Mr. Jordan Pollack said, “Our mission is to give surgeons the control they need to recanalize the veins of their patients safely, timely and successfully.  In doing so, we hope to inspire physicians to perform more venous recanalizations for the patients that need it to relieve pain and improve mobility. The procedure at University of Michigan Health was a huge step in changing the medical landscape of venous recanalization. We would like to thank the FDA for approving the use of Traversa in this first compassionate use case as well as Drs. Williams and Khaja for their agreement to try something new. We were honored to be of service.”


About University of Michigan Health, Michigan Medicine

At Michigan Medicine, we advance health to serve Michigan and the world. We pursue excellence every day in our five hospitals, 125 clinics and home care operations that handle more than 2.3 million outpatient visits a year, as well as educate the next generation of physicians, health professionals and scientists in our U-M Medical School.

Michigan Medicine includes the top ranked U-M Medical School and University of Michigan Health, which includes the C.S. Mott Children’s Hospital, Von Voigtlander Women’s Hospital, University Hospital, the Frankel Cardiovascular Center, Kellogg Eye Center, University of Michigan Health West and the Rogel Cancer Center. The U-M Medical School is one of the nation’s biomedical research powerhouses, with total research funding of more than $500 million.

More information is available at


About VeinWay

VeinWay provides physicians with a dedicated, purpose-built tool to create a pathway through a clogged vein such that physicians can easily restore blood flow through the vein to the heart. This tool is built to expand the physician’s ability to safely cross a variety of complicated blockages that were previously un-crossable, as well as shorten the time to cross.

VeinWay addresses an annual market of more than 1.7M Deep Vein Thrombosis (DVT) patients, half of which will return with Post Thrombotic Syndrome (PTS) within three to five years and 68% of those will have fully blocked veins. Traversa was developed by VeinWay as part of the MEDX Xelerator’s Entrepreneur-in-Residence program designed to promote breakthrough innovation. VeinWay is a portfolio company of the MEDX Xelerator, a medical device incubator backed by Boston Scientific, Sheba Medical Center, MEDX Ventures Group, Consensus Business Group (CBG), and West Pharmaceuticals. The company is currently engaged in an A financing round.


Press Contact:


Marjie Hadad

General Manager

Must Have Communication & Consulting

On behalf of VeinWay

[email protected]



This website uses cookies

We use cookies to enhance your experience on our site. Visit our Privacy Policy and Terms and Conditions of Use to learn more. By using our site, you agree to our use of cookies.

Agree | Learn More
Subscribe to Newsletter